Next Article in Journal
The Association between Malnutrition and Psychological Distress in Patients with Advanced Head-and-Neck Cancer
Previous Article in Journal
Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 6
10.3747/co.20.1596
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

by
I. Yildiz
1,*,
F. Sen
1,
L. Kilic
1,
M. Ekenel
1,
C. Ordu
1,
I. Kilicaslan
2,
E. Darendeliler
3,
H.M. Tunc
4,
U. Varol
5,
S. Bavbek
1 and
M. Basaran
1
1
Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey
2
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3
Department of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey
4
Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
5
Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(6), 546-553; https://doi.org/10.3747/co.20.1596
Submission received: 5 September 2013 / Revised: 8 October 2013 / Accepted: 7 November 2013 / Published: 1 December 2013

Abstract

Objective: We investigated the prognostic clinicopathologic factors associated with overall survival (OS) and progression-free survival (PFS) in the once-daily continuous administration of first-line sunitinib in a consecutive cohort of Turkish patients with metastatic renal cell carcinoma (RCC). Methods: The study enrolled 77 Turkish patients with metastatic RCC who received sunitinib in a continuous once-daily dosing regimen between April 2006 and April 2011. Univariate analyses were performed using the log-rank test. Results: Median follow-up was 18.5 months. In univariate analyses, poor PFS and OS were associated with 4 of the 5 factors in the Memorial Sloan–Kettering Cancer Center (MSKCC) score: Eastern Cooperative Oncology Group performance status of 2 or higher, low hemoglobin, high corrected serum calcium, and high lactate dehydrogenase. In addition to those factors, hypoalbuminemia, more than 2 metastatic sites, liver metastasis, non–clear cell histology, and the presence of sarcomatoid features on pathology were also associated with poor PFS; and male sex, hypoalbuminemia, prior radiotherapy, more than 2 metastatic sites, lung metastasis, nuclear grade of 3 or 4 for the primary tumour, and the presence of sarcomatoid features were also associated with poorer OS. The application of the MSKCC model distinctly separated the PFS and OS curves (p < 0.001). Conclusions: Our study identified prognostic factors for PFS and OS with the use sunitinib as first-line metastatic RCC therapy and confirmed that the MSKCC model still appears to be valid for predicting survival in metastatic RCC in the era of molecular targeted therapy.
Keywords: metastatic renal cell carcinoma; prognostic factors; sarcomatoid features; first-line therapy; vascular endothelial growth factor; vegf antagonist metastatic renal cell carcinoma; prognostic factors; sarcomatoid features; first-line therapy; vascular endothelial growth factor; vegf antagonist

Share and Cite

MDPI and ACS Style

Yildiz, I.; Sen, F.; Kilic, L.; Ekenel, M.; Ordu, C.; Kilicaslan, I.; Darendeliler, E.; Tunc, H.M.; Varol, U.; Bavbek, S.; et al. Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Curr. Oncol. 2013, 20, 546-553. https://doi.org/10.3747/co.20.1596

AMA Style

Yildiz I, Sen F, Kilic L, Ekenel M, Ordu C, Kilicaslan I, Darendeliler E, Tunc HM, Varol U, Bavbek S, et al. Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Current Oncology. 2013; 20(6):546-553. https://doi.org/10.3747/co.20.1596

Chicago/Turabian Style

Yildiz, I., F. Sen, L. Kilic, M. Ekenel, C. Ordu, I. Kilicaslan, E. Darendeliler, H.M. Tunc, U. Varol, S. Bavbek, and et al. 2013. "Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma" Current Oncology 20, no. 6: 546-553. https://doi.org/10.3747/co.20.1596

APA Style

Yildiz, I., Sen, F., Kilic, L., Ekenel, M., Ordu, C., Kilicaslan, I., Darendeliler, E., Tunc, H. M., Varol, U., Bavbek, S., & Basaran, M. (2013). Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Current Oncology, 20(6), 546-553. https://doi.org/10.3747/co.20.1596

Article Metrics

Back to TopTop